Perrigo (PRGO) Stock
Global manufacturer of medicines and baby formulas. Here's the price, business snapshot, and what's worth knowing about Perrigo in June 2026.
Perrigo Company plc (PRGO) is a global consumer healthcare manufacturer best known for over‑the‑counter medicines, infant formulas and private‑label personal care products sold through supermarkets, pharmacies and online retailers. With a market capitalisation around $3.02 billion, Perrigo blends manufacturing scale with long‑term retailer relationships and a focus on branded and store‑brand consumer goods. Investors should note the company’s exposure to retail channels, commodity and input‑costs, and regulatory oversight that can affect margins and product launches. Perrigo has pursued portfolio reshaping and cost measures in recent years to stabilise margins, but sales and profits can fluctuate with pricing pressure, competition and supply‑chain disruption. This summary is for educational purposes only and not personalised investment advice; past performance is not a reliable indicator of future returns and suitability depends on your circumstances.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Perrigo's stock with a target price of $18.67, indicating good potential growth.
Financial Health
Perrigo is generating solid revenue and cash flow, with a decent profit margin, although challenges exist.
Dividend
Perrigo's high dividend yield of 8.8% makes it an attractive choice for investors seeking dividend income. If you invested $1000, you would be paid $88 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
ASTRAZENECA PLC
AstraZeneca is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines.
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
Baskets Featuring PRGO
Defensive Equities | Risks in a Slowing Labour Market
After the U.S. economy unexpectedly shed 92,000 jobs in February, investors are seeking shelter from the resulting market volatility. This collection features resilient, non-cyclical companies that historically maintain their value and offer stability during periods of economic deceleration.
Published: 9 March 2026
Explore BasketJ&J Talc Crisis Impact Explained | Health Stocks
A jury verdict found Johnson & Johnson liable in a talc cancer case, one of over 63,000 similar lawsuits the company faces. This ongoing legal crisis may drive consumers toward competitors, creating an investment opportunity in other personal care and consumer health companies.
Published: 15 February 2026
Explore BasketDrug Pricing Deals Drive US Manufacturing in 2025
Johnson & Johnson secured a deal with the U.S. government to lower drug prices in exchange for tariff exemptions, expanding on a major policy trend. This theme identifies opportunities among pharmaceutical companies and domestic manufacturers benefiting from government incentives to onshore production.
Published: 9 January 2026
Explore BasketPharma Onshoring: What's Next for US Drug Supply
Merck is investing $3 billion in a new Virginia plant, signaling a major push for domestic pharmaceutical production. This theme focuses on companies poised to benefit from the broader trend of onshoring the U.S. drug supply chain.
Published: 21 October 2025
Explore BasketPharmaceutical Policy Shift Explained | Pricing Models
The Trump administration's recent drug pricing agreements with major pharmaceutical companies like AstraZeneca and Pfizer aim to lower U.S. drug costs by tying them to international prices. This creates a potential investment opportunity in pharmaceutical firms with strong domestic production and those in the healthcare supply chain that can adapt to the new pricing landscape.
Published: 12 October 2025
Explore BasketDomestic Pharma Tariffs: What's Next for Investors
The U.S. government has imposed a 100% tariff on pharmaceuticals from companies lacking domestic manufacturing, aiming to reshore production. This policy creates a significant advantage for U.S.-based pharmaceutical companies and their supply chains, which are poised for growth as reliance on imports decreases.
Published: 26 September 2025
Explore BasketWalgreens Restructuring Explained: Investment Shifts
Following its acquisition by Sycamore Partners, Walgreens has gone private and split into five companies. This theme explores the investment opportunities created by the newly independent healthcare and retail entities.
Published: 2 September 2025
Explore BasketWalgreens' Restructuring: A New Healthcare Landscape
Following its $10 billion acquisition by Sycamore Partners, Walgreens is going private and splitting into five separate companies. This major restructuring of a key industry player could create significant opportunities for competitors and specialized healthcare service providers to capture market share.
Published: 29 August 2025
Explore BasketNavigating Pharma Price Controls
President Trump's ultimatum to major pharmaceutical firms to lower drug prices creates significant market uncertainty for brand-name drug makers. This situation could benefit companies that thrive on reducing healthcare costs, such as generic drug manufacturers and prescription discount platforms.
Published: 4 August 2025
Explore BasketWhy You’ll Want to Watch This Stock
Private‑label strength
Perrigo’s long relationships with retailers support steady sales in store‑brand products, though pricing pressure can squeeze margins.
Global distribution reach
A broad footprint gives scale and channel diversity, but exposes the company to currency, regulatory and regional demand risks.
Margins and costs
Operating profits are sensitive to input and freight costs; cost control helps, yet performance can vary with macro and supply‑chain shifts.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
